Angioedema: 6 years experience with fourteen cases

Auris Nasus Larynx

Volumn 37, Issue 2, 2010, Pages 199-204

  Taki, Masakatsu ^a   Watanabe, Hiroki ^a   Hasegawa, Tatsuhisa ^a   Bamba, Hitoshi ^a   Shimada, Taketoshi ^a   Hisa, Yasuo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Angioedema; Angiotensin converting enzyme inhibitor (ACEI); Angiotensin II receptor blocker (ARB); Tracheotomy

Indexed keywords

ALACEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; LISINOPRIL; STEROID; TEMOCAPRIL; TRANDOLAPRIL;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE MARKER; DRUG WITHDRAWAL; ENZYME ACTIVITY; FACE EDEMA; FEMALE; HEAD AND NECK DISEASE; HUMAN; INFLAMMATION; INTUBATION; LARYNX EDEMA; LEUKOCYTE COUNT; MALE; MEDIASTINUM DISEASE; MEDIASTINUM EDEMA; MOUTH EDEMA; NECK EDEMA; PENIS DISEASE; PENIS EDEMA; PLEURA EFFUSION; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RELAPSE; REMISSION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TONGUE EDEMA;

AGED; AIRWAY OBSTRUCTION; ANGIOEDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; RETROSPECTIVE STUDIES; RISK; TETRAZOLES;

EID: 74149089849     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2009.07.006     Document Type: Article

References (27)

1. Ishoo E., Shah U.K., Grillone G.A., Stram J.R., and Fuleihan N.S. Predicting airway risk in angioedema: staging system based on presentation. Otolaryngol Head Neck Surg 121 (1999) 263-268
2. Zirkle M., and Bhattacharyya N. Predictors of airway intervention in angioedema of the head and neck. Otolaryngol Head Neck Surg 123 (2000) 240-245
3. Chiu A.G., Newkirk K.A., Davidson B.J., Burningham A.R., Krowiak E.J., and Deeb Z.E. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 110 (2001) 834-840
4. Slater E.E., Merrill D.D., Guess H.A., Roylance P.J., Cooper W.D., Inman W.H., et al. Clinical profile of angioedema associated with angiotensin-converting enzyme inhibition. JAMA 260 (1988) 967-970
5. Israili Z.H., and Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 117 (1992) 234-242
6. Brown N.J., Ray W.A., Snowden M., and Griffin M.R. Black Americans have an increased rate of angiotensin converting inhibitor-associated angioedema. Clin Pharmacol Ther 60 (1996) 8-13
7. Sweitzer N.K. Cardiology patient page. What is an angiotensin converting enzyme inhibitor?. Circulation 108 (2003) e16-e18
8. Sabroe R.A., and Black A.K. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 136 (1997) 153-158
9. Chiu A.G., Krowiak E.J., and Deep Z.E. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 111 (2001) 1729-1731
10. Howes L.G., and Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?. Drug Saf 25 (2002) 73-76
11. Lo K.S. Angioedema associated with candesartan. Pharmacotherapy 22 (2002) 1176-1179
12. Nykamp D., and Winter E.E. Olmesartan medoxomil-induced angioedema. Ann Pharmacother 41 (2007) 518-520
13. Kyrmizakis D.E., Papadakis C.E., Liolios A.D., Karatzanis A.D., Malandrakis S., Skoulakis C.E., et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg 130 (2004) 1416-1419
14. Campbell D.J., Krum H., and Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 (2005) 315-320
15. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., and Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351 (1998) 1693-1697
16. Nussberger J., Cugno M., and Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 347 (2002) 621-622
17. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., and Davis III A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 (2002) 1057-1063
18. Brasher G.W., Starr J.C., Hall F.F., and Spiekerman A.M. Complement component analysis in angioedema: Diagnostic value. Arch Dermatol 111 (1975) 1140-1142
19. Bas M., Hoffmann T.K., Bier H., and Kodja G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 59 (2005) 233-238
20. Quincke H. Über akutes umshriebenes Hautödem. Monatsh Prakt Dermatol 1 (1882) 129-131
21. Grant N.N., Deeb Z.E., and Chia S.H. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg 137 (2007) 931-935
22. Kaplan A.P., Joseph K., and Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109 (2002) 195-209
23. Hosoi K., Tsunasawa S., Kurihara K., Aoyama H., Ueha T., Murai T., et al. Identification of mK1, a true tissue (glandular) kallikrein of mouse submandibular gland: tissue distribution and a comparison of kinin-releasing activity with other submandibular kallikreins. J Biochem 115 (1994) 137-143
24. Wei W., Parvin N., Tsumura K., Akamatsu T., Tada J., Kanamori N., et al. Induction of C-reactive protein, serum amyloid P component, and kininogens in the submandibular and lacrimal glands of rats with experimentally induced inflammation. Life Sci 69 (2001) 359-368
25. Carr A.A., and Prisant L.M. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 36 (1996) 3-12
26. Dirks K., Deuerling J., and Lutz H. Sonography in hereditary angioedema: typical findings demonstrated by the example of 3 cases. Ultraschall Med 22 (2001) 186-190
27. Package insert. Atacand (candesartan cilexetil) (2003), AstraZeneca, Wilmington, DE